All In Biotech

NDA 022260 · Actelion

Veletri

Epoprostenol Sodium · Injection · Prostacycline Vasodilator

Last checked: Nov 20, 2026Latest source record: Oct 21, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Jun 27, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

92

18 Phase 3, 9 recruiting

FAERS reports

13,102

11,321 serious, 2,715 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 28, 2022.

VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. VELETRI is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. ( 1 )

Mechanism: Epoprostenol has 2 major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VELETRI · EPOPROSTENOL SODIUM EQ 0.5MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP2
  • VELETRI · EPOPROSTENOL SODIUM EQ 1.5MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP2

Clinical trials

Interventional ClinicalTrials.gov studies with "Epoprostenol" as an intervention, any sponsor and status, largest first.

All 92 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,785
  • headache2,302
  • diarrhoea2,178
  • nausea1,970
  • pain in jaw1,859
  • death1,329
  • flushing1,174
  • fatigue1,117
  • pulmonary arterial hypertension1,105
  • vomiting1,051
  • dyspnoea exertional969
  • fluid retention926

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
200510
20061
200924
201016
201152
2012328
2013680
20141,381
20151,504
20161,492
20171,275
20181,345
20191,075
20201,006
2021577
2022576
2023447
2024503
2025474
2026331

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Veletri (Epoprostenol Sodium)

2024 spending

$606K

Beneficiaries

22

223 claims

Per beneficiary

$27,530

$52.49 per unit

View as table
YearSpending
2020$145,811
2021$545,538
2022$742,880
2023$759,548
2024$605,651

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 141 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.